Skip to main content
NCBI home page
Acta Neuropathologica Communications logoLink to Acta Neuropathologica Communications
. 2021 Sep 29;9:161. doi: 10.1186/s40478-021-01258-8

Correction to: The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson’s disease

David I Finkelstein 1,✉, Jessica L Billings 1, Paul A Adlard 1, Scott Ayton 1, Amelia Sedjahtera 1, Colin L Masters 1, Simon Wilkins 1, David M Shackleford 3, Susan A Charman 3, Wojciech Bal 4, Izabela A Zawisza 4, Ewa Kurowska 4, Andrew L Gundlach 1, Sheri Ma 1, Ashley I Bush 1, Dominic J Hare 1,5, Philip A Doble 5, Simon Crawford 6, Elisabeth C L Gautier 2, Jack Parsons 2, Penny Huggins 2, Kevin J Barnham 1,7, Robert A Cherny 1,2,✉
PMCID: PMC8482648  PMID: 34588001

Correction to: Acta Neuropathologica Communications (2017) 5:53 https://doi.org/10.1186/s40478-017-0456-2

Following publication of the original article [1], the author identified an error in Fig. 4E. The data and statistics were correct, but the synaptophysin blot was incorrect.

The incorrect (Fig. 1) and correct figure (Fig. 2) are shown in this correction article.

Fig. 1.

Fig. 1

Open in a new tab

Incorrect version of Fig. 4E as originally published

Fig. 2.

Fig. 2

Open in a new tab

Correct version of Fig. 4E

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Contributor Information

David I. Finkelstein, Email: d.finkelstein@florey.edu.au

Robert A. Cherny, Email: rcherny@unimelb.edu.au

Reference

  • 1.Finkelstein DI, Billings JL, Adlard PA, et al. The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson’s disease. Acta Neuropathol Commun. 2017;5:53. doi: 10.1186/s40478-017-0456-2. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Acta Neuropathologica Communications are provided here courtesy of BMC

RESOURCES